Search Results

You are looking at 91 - 100 of 203 items for :

  • "lymph node dissection" x
  • Refine by Access: All x
Clear All
Full access

Fiona Tsui-Fen Cheng, Fu Ou-Yang, Nina Lapke, Kai-Che Tung, Yen-Kung Chen, Yuh-Yu Chou, and Shu-Jen Chen

Case Report A 47-year-old Asian woman presented at our institution with stage IIIA (T1cN2M0) invasive ductal carcinoma. She underwent breast-conserving surgery and axillary lymph node dissection. Her tumor was found to be grade II, estrogen

Full access

Presenters: Valencia D. Thomas, Michael K. Wong, and Andrew J. Bishop

—this, according to Dr. Bishop, was enough of a response to render the tumor resectable. Sixteen lymph nodes were removed during axillary lymph node dissection and were negative for any viable metastatic carcinoma, resulting in a pathologic CR. According to Dr

Full access

Venkata Pokuri, Norbert Sule, Yousef Soofi, Bo Xu, Khurshid Guru, and Saby George

. Therefore, chemotherapy was discontinued and she underwent a robot-assisted radical cystectomy with open construction of an ileal neobladder and an extended bilateral pelvic lymph node dissection. Figure 1 CT scan showing irregular necrotic mass at

Full access

Chunkit Fung, Paul C. Dinh Jr, Sophie D. Fossa, and Lois B. Travis

management strategy for stage I TC. 14 For stage I nonseminoma, adjuvant chemotherapy with 1 cycle of bleomycin/etoposide/cisplatin (BEPX1) and retroperitoneal lymph node dissection (RPLND) are other options, whereas adjuvant chemotherapy with 1 cycle of

Full access

Philippe E. Spiess

node dissection (ILND) is recommended, and again DSNB is a category 2B recommendation. “We are somewhat cautious in promoting this type of technique [DSNB],” admitted Dr. Spiess. For those with more aggressive primary tumor, the gold standard remains

Full access

Stanley J. Miller, Murad Alam, James Andersen, Daniel Berg, Christopher K. Bichakjian, Glen Bowen, Richard T. Cheney, L. Frank Glass, Roy C. Grekin, Anne Kessinger, Nancy Y. Lee, Nanette Liegeois, Daniel D. Lydiatt, Jeff Michalski, William H. Morrison, Kishwer S. Nehal, Kelly C. Nelson, Paul Nghiem, Thomas Olencki, Clifford S. Perlis, E. William Rosenberg, Ashok R. Shaha, Marshall M. Urist, Linda C. Wang, and John A. Zic

regional lymph node dissection following the corresponding pathway for the head and neck region (see page 845) or the trunk and extremity region (see page 846). Radiation alone is an alternative when surgery is not initially feasible; however, after

Full access

Eve Henry, Victor Villalobos, Lynn Million, Kristin C. Jensen, Robert West, Kristen Ganjoo, Alexandra Lebensohn, James M. Ford, and Melinda L. Telli

have a 2.7-cm moderately differentiated invasive ductal carcinoma that was estrogen receptor–positive/progesterone receptor–positive/HER2-positive (ER+/PR+/HER2+) on immunohistochemistry. Lymph node dissection was negative in 0 of 23 nodes. Surgical

Full access

John P. Sherbeck, Lili Zhao, and Richard W. Lieberman

. Int J Gynecol Cancer 2015 ; 25 : 1437 – 1444 . 5. Alagkiozidis I Weedon J Grossman A . Extent of lymph node dissection and overall survival in patients with uterine carcinosarcoma, papillary serous and endometrioid adenocarcinoma: a

Full access

Andrew L. Ji, Christopher K. Bichakjian, and Susan M. Swetter

predictor of survival and determines the indication for additional surgery (ie, complete lymph node dissection), systemic adjuvant therapy, surveillance imaging, and frequency of clinical follow-up. However, controversy remains regarding the most appropriate

Full access

Prashant Gabani, Emily Merfeld, Amar J. Srivastava, Ashley A. Weiner, Laura L. Ochoa, Dan Mullen, Maria A. Thomas, Julie A. Margenthaler, Amy E. Cyr, Lindsay L. Peterson, Michael J. Naughton, Cynthia Ma, and Imran Zoberi

Adjuvant chemotherapy was also administered in 46 patients (30.1%). A total of 73 patients (47.7%) underwent breast-conserving surgery, and 118 (77.1%) underwent axillary lymph node dissection. The rate of pCR was 29.4% (n=45). Most patients (81